NRAS and melanoma: In contrast, melanomas with WT BRAF, NRAS and NF1 that are driven by activating KIT mutations can be treated with the RTK inhibitor imatinib, yielding response rates of 16–30% (Carvajal et al., 2011; Guo et al., 2011; Hodi et al., 2013); however, most of these responses were partial and transient.